BiotechTube

AU-011

Pre-clinicalTerminated
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Choroidal Melanoma

Conditions

Choroidal Melanoma, Indeterminate Lesions

Trial Timeline

Apr 14, 2022 → Apr 20, 2023

NCT ID
NCT05266430

About AU-011

AU-011 is a pre-clinical stage product being developed by Aura Biosciences for Choroidal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05266430. Target conditions include Choroidal Melanoma, Indeterminate Lesions.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (4)

NCT IDPhaseStatus
NCT06643884Phase 2Recruiting
NCT05483868Phase 1Recruiting
NCT05266430Pre-clinicalTerminated
NCT04417530Phase 2Completed

Competing Products

20 competing products in Choroidal Melanoma

See all competitors
ProductCompanyStageHype Score
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
85
ranibizumabNovartisApproved
85
RanibizumabNovartisApproved
85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
77
ranibizumabNovartisPhase 3
77
Everolimus + RanibizumabNovartisPhase 2
52
RanibizumabNovartisPhase 3
77
ranibizumab 0.5mgNovartisPhase 2
52
ranibizumabNovartisPhase 3
77
Brolucizumab 6mg + Brolucizumab 6mgNovartisPhase 3
77
Intravitreal injection ranibizumabNovartisPhase 2
52
RanibizumabNovartisPhase 3
77
RanibizumabNovartisPhase 1/2
41
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
52
Faricimab + RanibizumabRochePhase 3
77
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
52
Intravitreal PegaptanibPfizerPre-clinical
22
Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
84

Other Products from Aura Biosciences

Bel-sarPhase 3
69
AU-011Phase 2
44
AU-011Phase 2
44
Light-activated AU-011Phase 1/2
33
AU-011Phase 1
25